About Ovensa

Ovensa Inc. is a Canadian, preclinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform, with mucosal and brain-barrier crossing properties, to generate advanced nanotherapeutics, that enhance the bioavailability and the targeted intracellular uptake of small molecules and biologics through oral and other routes of administration. Ovensa mainly focuses on oncology. Its development programs also aim at generating validation data in neurodegenerative diseases and antibiotic resistance.

Partnering

Ovensa is seeking for strategic partnerships with pharmaceutical, generic and biotech companies interested to reformulate or repurpose proprietary and off-patent molecules (biologic and small molecule) with its TRIOZAN™ Nanomedicine Delivery Platform applicable in a fast track regulatory approval pathway.